CNCR

Fund Description
The Loncar Cancer Immunotherapy ETF seeks to track the LCINDX index. It is made up of a basket of companies that develop therapies to treat cancer by harnessing the body s own immune system. Immunotherapy is a transformational field within the biotechnology space that is expected to become the foundational treatment for cancer over the next ten years. A sector ETF focusing on a unique technology like cancer immunotherapy allows investors to focus on interest areas more precisely than broad indices. LCINDX is an equal-weighted index containing both large pharmaceutical and growth-oriented biotechnology companies that are leading in this approach.
Fund Profile
Fund Name Loncar Cancer Immunotherapy ETF
Fund Exchange Ticker CNCR
Fund Sponsor Exchange Traded Concepts
Fund ISIN US26922A8264
Net Expense Ratio 0.79 %
Fund Inception Date 13 October 2015
Fund Legal Structure ETF (Open end fund)
Exchange NASDAQ
Listing Country Code US
Fund Investment Objective
ETF Type Specific US Equities - Industry Sector
Asset Class Equities (Stocks)
Index Linked Passive
Index Name Loncar Cancer Immunotherapy Index
Index Provider Loncar Investments
Currency Hedged No
Inverse / Leveraged Not Applicable
Developed / Emerging Developed Market Funds
Market Capitalization Range Broad Market / Multi-Cap
Growth Value Core / Blend
Continent North America
Key Statistics
Return As of Date 14 January 2021
Asset Under Management 52.53 Million (USD)
1 Month Total Return 5.86 %
Year To Date Return 10.34 %
1 Year Total Return 50.02 %
3 Year Annualized Total Return 11.17 %
NAV 35.0178
Share Outstanding 1,500,000
Top 10 Holdings (14 January 2021)
Constituent Name Constituent Ticker Constituent Type Weighting
BEIGENE LTD-ADR BGNE EQUI 0.0476000000
I MAB IMAB EQUI 0.0420000000
CRISPR THERAPEUTICS AG CRSP EQUI 0.0408000000
ARCUS BIOSCIENCES INC RCUS EQUI 0.0394000000
SCHOLAR ROCK HOLDING CORP SRRK EQUI 0.0378000000
BLUEBIRD BIO INC BLUE EQUI 0.0373000000
ALLOGENE THERAPEUTICS INC ALLO EQUI 0.0372000000
FATE THERAPEUTICS INC FATE EQUI 0.0369000000
TRILLIUM THERAPEUTICS INC TRIL EQUI 0.0368000000
GENMAB A/S -SP ADR GMAB EQUI 0.0360000000